Omez | Vistara Edge

How to use

Duodenal Ulcer

The recommended adult oral dose for the short-term treatment of duodenal ulcer is 20mg, once daily for 4 weeks
Sometimes the treatment may require an additional 4 week

How to use

Gastric Ulcer

The recommended adult dose is 40mg once daily for 4 - 8 weeks
For prevention of relapse in patients with duodenal ulcer the recommended dose is Omeprazole 10mg once daily
Increasing to 20mg once daily if symptoms return
For patients who are at risk from recurrent ulcer relapse i.e. those with Helicobacter Pylori infection younger
patients (<60 years), patients whose symptoms persist for more than one year, and smokers, long-term therapy
should be initiated.
With omeprazole 20mg once daily, and reducing it to10mg once daily, if necessary.

Reflux Oesophagitis

For the short-term treatment of reflux oesophagitis with only symptomatic gastroesophageal reflux disease (GERD)
and no oesophageal lesions
The recommended adult dose is 20mg once daily for 4 weeks
For patients with erosive oesophagitis and accompanying symptoms of GERD, the recommended
dose is 20 mg once daily for 4-8 weeks
Omeprazole 40 mg/day can be used in patients with reflux oesophagitis refractory to other therapy
Healing usually occurs within 8 weeks
Patients can be continued at a dosage of 20 mg once daily maintenance of healing of erosive oesophagitis
The usual adult oral dose is 20mg daily

Zollinger-Ellison Syndrome

The recommended starting oral dose is 60mg once daily
The doses can be varied with individual patients’ need and treatment should be continued as long as clinically indicated
Doses up to 120mg t.i.d have been administered
With doses above 80mg daily, the dose should be divided and given twice daily

The Association of Physicians of India (API) recognises Omeprazole as a Safer PPI in APD management¹

Hepatic Safety

As per the review and analysis of 69 articles by an expert panel published in the British Journal of Clinical Pharmacology (August 2018)³
Omeprazole – Safer in CTP A and CTP B patients than pantoprazole
Omeprazole – PPI with "no additional risks known" for cirrhotic patients

Renal Safety

According to a clinical trial conducted in 5994 patients, International Diabetes Federation (2019)⁴
No associated increase in the risk of CKD with Omeprazole after 1 year of use
Omeprazole – PPI of choice in diabetic patients over pantoprazole

COVID compliance

WHO recommends Omeprazole as one of the useful oral medicines for prevention and relief of physical suffering related to Covid-19⁶
Omeprazole is the only PPI featuring in WHO Covid 19 Clinical management guidelines

Pregnancy safety

According to World Gastroenterology Global Guidelines (July 2017)⁵
Omeprazole (only Category B PPI) has the largest human experience for use in pregnancy

Safety in Geriatric and Pediatric
Populations

As per the US FDA, Omeprazole has proven safety in geriatric and pediatric populations²

Omeprazole is not only safe but
also affordable

Omeprazole is 66% economical than leading pantoprazole brands*

1. S. Arhulraj, Mangesh Tiwaskar, T. S. Chandrasekar Acid-Peptic Disorder Management:- Omeprazole, A Safer Option: Thieme Publishing Group, Delhi.2020 p.7-36.
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf. Accessed on 27.10.2021.
3. Weersink RA et. al., Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018 Aug;84(8):1806–20.
4. Yang H et. al., Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Res Clin Pract. 2019 Jan;147:67–75.
5. Hunt et. al., World Gastroenterology Organisation Global Guidelines, Journal of Clinical Gastroenterology: July 2017 - Volume 51 - Issue 6 - p 467-78.
6. https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-eng.pdf.
7. Omez capsule: View uses, side effects, price and substitutes (18 September 2024) 1mg.
8. Talley NJ, Zand Irani M. Optimal management of severe symptomatic gastroesophageal reflux disease. Journal of Internal Medicine. 2020 Jul 21;289(2):162-78.
* Average Costing for top selling brands for each molecule
# Deduced from CDSCO indication

The Association of Physicians of India (API) recognises
Omeprazole as a Safer PPI in APD management¹

Hepatic Safety

As per the review and analysis of 69 articles by an expert panel published in the British Journal of Clinical Pharmacology (August 2018)³
Omeprazole – Safer in CTP A and CTP B patients than pantoprazole
Omeprazole – PPI with "no additional risks known" for cirrhotic patients

Renal Safety

According to a clinical trial conducted in 5994 patients, International Diabetes Federation (2019)⁴
No associated increase in the risk of CKD with Omeprazole after 1 year of use
Omeprazole – PPI of choice in diabetic patients over pantoprazole

COVID compliance

WHO recommends Omeprazole as one of the useful oral medicines for prevention and relief of physical suffering related to Covid-19⁶
Omeprazole is the only PPI featuring in WHO Covid 19 Clinical management guidelines

Pregnancy safety

According to World Gastroenterology Global Guidelines (July 2017)⁵
Omeprazole (only Category B PPI) has the largest human experience for use in pregnancy

Safety in Geriatric and Pediatric
Populations

As per the US FDA, Omeprazole has proven safety in geriatric and pediatric populations²

Omeprazole is not only safe but
also affordable

Omeprazole is 66% economical than leading pantoprazole brands*

1. S. Arhulraj, Mangesh Tiwaskar, T. S. Chandrasekar Acid-Peptic Disorder Management:- Omeprazole, A Safer Option: Thieme Publishing Group, Delhi.2020 p.7-36.
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf. Accessed on 27.10.2021.
3. Weersink RA et. al., Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018 Aug;84(8):1806–20.
4. Yang H et. al., Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Res Clin Pract. 2019 Jan;147:67–75.
5. Hunt et. al., World Gastroenterology Organisation Global Guidelines, Journal of Clinical Gastroenterology: July 2017 - Volume 51 - Issue 6 - p 467-78.
6. https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-eng.pdf.
7. Omez capsule: View uses, side effects, price and substitutes (18 September 2024) 1mg.
8. Talley NJ, Zand Irani M. Optimal management of severe symptomatic gastroesophageal reflux disease. Journal of Internal Medicine. 2020 Jul 21;289(2):162-78.
* Average Costing for top selling brands for each molecule
# Deduced from CDSCO indication

Duodenal Ulcer

Gastric Ulcer

Reflux Oesophagitis

Zollinger-Ellison Syndrome

KOL Videos

Acid-Peptic Disease-How to Treat?

Therapy Videos

Safety in Acidity

Duodenal Ulcer

Gastric Ulcer

Reflux Oesophagitis

Zollinger-Ellison Syndrome

KOL Videos

Acid-Peptic Disease-How to Treat?

Acid-Peptic Disease-How to Treat?

Acid-Peptic Disease-How to Treat?

Webinar Speakers

Therapy Videos

Safety in Acidity

Safety in Acidity

Safety in Acidity

Videos Speakers

Login to continue